University of Liverpool-ko ikertzaileekin lankidetzan egindako argitalpenak (16)

2024

  1. Non-binary gender, vulnerable populations and mental health during the COVID-19 pandemic: Data from the COVID-19 MEntal health inTernational for the general population (COMET-G) study

    Journal of Affective Disorders, Vol. 352, pp. 536-551

  2. Somatic multicomorbidity and disability in patients with psychiatric disorders in comparison to the general population: a quasi-epidemiological investigation in 54,826 subjects from 40 countries (COMET-G study)

    CNS Spectrums, Vol. 29, Núm. 2, pp. 126-149

2023

  1. Results of the COVID-19 mental health international for the health professionals (COMET-HP) study: depression, suicidal tendencies and conspiracism

    Social Psychiatry and Psychiatric Epidemiology, Vol. 58, Núm. 9, pp. 1387-1410

2022

  1. Results of the COVID-19 mental health international for the general population (COMET-G) study

    European Neuropsychopharmacology, Vol. 54, pp. 21-40

  2. The effect of different degrees of lockdown and self-identified gender on anxiety, depression and suicidality during the COVID-19 pandemic: Data from the international COMET-G study.

    Psychiatry Research, Vol. 315

2020

  1. Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: A sub-study of the NEAT001/ANRS143 randomized trial

    Journal of Antimicrobial Chemotherapy, Vol. 75, Núm. 3, pp. 628-639

2019

  1. HIV-1 molecular transmission clusters in nine European countries and Canada: Association with demographic and clinical factors

    BMC Medicine, Vol. 17, Núm. 1

2018

  1. Life-threatening infections in children in Europe (the EUCLIDS Project): a prospective cohort study

    The Lancet Child and Adolescent Health, Vol. 2, Núm. 6, pp. 404-414

2012

  1. A clozapine-like effect of cyproheptadine on progressive ratio schedule performance

    Journal of Psychopharmacology, Vol. 26, Núm. 6, pp. 857-870

  2. Intrapatient and interpatient pharmacokinetic variability of raltegravir in the clinical setting

    Therapeutic Drug Monitoring, Vol. 34, Núm. 2, pp. 232-235

2011

  1. Challenges and opportunities for hepatitis C drug development in HIV-hepatitis C virus-co-infected patients

    AIDS, Vol. 25, Núm. 18, pp. 2197-2208

  2. Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunction

    Journal of Infectious Diseases, Vol. 204, Núm. 1, pp. 145-153

2010

  1. Population pharmacokinetic modeling of the association between 63396C→T pregnane X receptor polymorphism and unboosted atazanavir clearance

    Antimicrobial Agents and Chemotherapy, Vol. 54, Núm. 12, pp. 5242-5250

2009

  1. Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir:A harmacogenetic study

    Clinical Infectious Diseases, Vol. 48, Núm. 11

2007

  1. Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment

    Expert Opinion on Pharmacotherapy, Vol. 8, Núm. 5, pp. 679-688

2005

  1. Effect of ribavirin on intracellular and plasma pharmacokinetics of nucleoside reverse transcriptase inhibitors in patients with human immunodeficiency virus-hepatitis C virus coinfection: Results of a randomized clinical study

    Antimicrobial Agents and Chemotherapy, Vol. 49, Núm. 10, pp. 3997-4008